Cargando…

Prediction models for development of hepatocellular carcinoma in chronic hepatitis B patients

Chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC) is a major health problem in Asian-Pacific regions. Antiviral therapy reduces, but does not completely prevent, HCC development. Thus, there is a need for accurate risk prediction to assist prognostication and decisions on the need for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Jiang, Gao, Xue-Song
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107908/ https://www.ncbi.nlm.nih.gov/pubmed/34002133 http://dx.doi.org/10.12998/wjcc.v9.i14.3238

Ejemplares similares

Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients
por: Lee, Hye Won, et al.
Publicado: (2016)

Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it?
por: Demirtas, Coskun Ozer, et al.
Publicado: (2021)

Epidemiologic and socioeconomic factors impacting hepatitis B virus and related hepatocellular carcinoma
por: Gnyawali, Bipul, et al.
Publicado: (2022)

Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA
por: Liu, Ya-Yun, et al.
Publicado: (2018)

Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows
por: Guarino, Maria, et al.
Publicado: (2018)

Characterization of metabolic landscape in hepatocellular carcinoma
por: Wu, Jing, et al.
Publicado: (2021)

Risk of hepatocellular carcinoma after hepatitis C virus cure
por: Luna-Cuadros, Maria Alejandra, et al.
Publicado: (2022)

Discontinuation of antiviral therapy in chronic hepatitis B patients
por: Medas, Renato, et al.
Publicado: (2021)

Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure
por: Shinn, Brianna J, et al.
Publicado: (2019)

Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection
por: Irshad, Mohammad, et al.
Publicado: (2017)

Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals
por: Baumert, Thomas F., et al.
Publicado: (2017)

Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases
por: Kawanaka, Miwa, et al.
Publicado: (2021)

Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
por: Meringer, Hadar, et al.
Publicado: (2019)

Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review
por: Gigi, Eleni, et al.
Publicado: (2018)

Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
por: Kudo, Masatoshi
Publicado: (2019)

Challenges in the discontinuation of chronic hepatitis B antiviral agents
por: Kaewdech, Apichat, et al.
Publicado: (2021)

Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy
por: Zhang, Chun-Ye, et al.
Publicado: (2022)

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
por: Marisi, Giorgia, et al.
Publicado: (2018)

Chronic hepatitis B in pregnant women: Current trends and approaches
por: Belopolskaya, Maria, et al.
Publicado: (2021)

Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis
por: Wu, Ya-Li, et al.
Publicado: (2019)

Chronic hepatitis B: New potential therapeutic drugs target
por: Leowattana, Wattana, et al.
Publicado: (2022)

Treatment for hepatocellular carcinoma with tumor thrombosis in the hepatic vein or inferior vena cava: A comprehensive review
por: Zhang, Zun-Yi, et al.
Publicado: (2021)

Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma
por: Chen, Pu, et al.
Publicado: (2021)

Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end
por: Muzica, Cristina Maria, et al.
Publicado: (2020)

Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons
por: Luo, Yi, et al.
Publicado: (2022)

Is the treatment outcome of hepatocellular carcinoma inferior in elderly patients?
por: Chu, Kevin Ka Wan, et al.
Publicado: (2019)

Nutritional therapy for hepatocellular carcinoma
por: Ruiz-Margáin, Astrid, et al.
Publicado: (2021)

Immunotherapy for recurrent hepatocellular carcinoma
por: Bhatt, Ahan, et al.
Publicado: (2023)

Hepatitis B in renal transplant patients
por: Marinaki, Smaragdi, et al.
Publicado: (2017)

Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion
por: Li, Jiang, et al.
Publicado: (2023)

Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma
por: Takakura, Kazuki, et al.
Publicado: (2018)

Heterogeneity of immune control in chronic hepatitis B virus infection: Clinical implications on immunity with interferon-α treatment and retreatment
por: Yin, Guo-Qing, et al.
Publicado: (2022)

Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma
por: Zhao, Yang, et al.
Publicado: (2021)

Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease
por: Wong, Carrie R, et al.
Publicado: (2016)

Diagnostic value of imaging examinations in patients with primary hepatocellular carcinoma
por: Li, Xing-Hui, et al.
Publicado: (2018)

Radiomic advances in the transarterial chemoembolization related therapy for hepatocellular carcinoma
por: Chen, Tian-You, et al.
Publicado: (2023)

Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma
por: Song, Jeong Eun, et al.
Publicado: (2017)

Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate
por: Kamal, Ahmed, et al.
Publicado: (2022)

Molecular therapy for the treatment of hepatocellular carcinoma
por: Greten, T F, et al.
Publicado: (2009)

Dimensions of hepatocellular carcinoma phenotypic diversity
por: Désert, Romain, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1ujr9nh3ef5pudghag6rkeg6i0